PD-L1 was a key target of anticancer therapy, and its expression in tumor tissues of patients with renal cell carcinoma, esophageal carcinoma, gastric carcinoma, and ovarian cancer suggested poor prognosis [22]. This evidence concerns the gene CD274 and neoplasm.